Investigation of Interleukin-10 Promoter Polymorphisms and Interleukin-10 Levels in Children with Irritable Bowel Syndrome.
- Author:
Man Chin HUA
1
;
Hsun Chin CHAO
;
Tsung Chieh YAO
;
Ming Wei LAI
;
Jing Long HUANG
Author Information
1. Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan.
- Publication Type:Original Article
- Keywords:
Irritable bowel syndrome;
Child;
Interleukin-10;
Interleukin-10 gene polymorphisms
- MeSH:
Alleles;
Child;
DNA;
Escherichia coli;
Genetic Variation;
Genotype;
Haplotypes;
Humans;
Interleukin-10;
Interleukins;
Irritable Bowel Syndrome
- From:Gut and Liver
2013;7(4):430-436
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: The aim of this study was to investigate whether genetic variations at positions -1082, -819, and -592 in the interleukin (IL)-10 promoter affect IL-10 production in children with irritable bowel syndrome (IBS). METHODS: Ninety-four children with IBS and 102 children as healthy controls (HCs) were enrolled. Genomic DNA was extracted, and IL-10 -1082, -819, and -592 polymorphisms were detected by direct sequencing from all participants. Peripheral blood mononuclear cells (PBMCs) from 46 IBS children and 38 HCs were isolated and cultured with and without 5 ng/mL Escherichia coli lipopolysaccharide (LPS). IL-10 levels in the culture supernatants were measured by enzyme-linked immunosorbent assay. RESULTS: There were no significant differences in the distribution of IL-10 -1082, -819, and -592 polymorphisms or in the allele and haplotype frequencies between IBS children and HCs. PBMCs from children with IBS had significantly lower IL-10 levels after LPS stimulation than PBMCs from HCs (p=0.011); however, LPS-induced IL-10 levels in PBMCs with different genotypes of -819 and -592 polymorphisms were not significantly different between IBS patients and HCs. CONCLUSIONS: Although significantly lower LPS-induced IL-10 production by PBMCs was noted, it is unlikely that IL-10 production was fully genetically determined in our IBS children. ClinicalTrials.gov identifier: NCT01131442.
